Motif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, today announced positive topline results from REVIVE-1, a global Phase 3 clinical trial of its investigational drug candidate iclaprim in patients with acute bacterial skin and skin structure infections (ABSSSI).
SkinBioTherapeutics plc (AIM: SBTX, the “Company”), a life science company focused on skin health, announces the commencement of dealings in its Ordinary Shares on AIM 5 March 2017 under the ticker code SBTX and the ISIN number: GB00BF33H870.
Share Talk spoke to Declan Service, CEO of Integumen Plc about today’s IPO to the FTSE AIM market after a fundraise of £2.25M.
Share Talk presents a video of João Andrade’s investor presentation from our Innovative Investor’s Evening at the National Museum in Cardiff, 18 February 2017, sponsored by Financial Orbit Ltd and supported by SC Capital Ltd, St Brides Partners and Companies House.
This morning OptiBiotix Health Plc (AIM:OPTI) released significant news that they have signed a major manufacturing, supply and profit sharing deal with Sacco, one of Europe’s leading suppliers of probiotics ingredients.
WideCells Group PLC, the healthcare services company focused on providing stem cell services and ground breaking insurance for stem cell treatment, is pleased to provide an update on the continued commercialisation of its 100% owned subsidiary CellPlan Limited (‘CellPlan’), which has developed the world’s first stem cell healthcare insurance plan and medical concierge service.